Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from pharmacy benefit managers. The companies are typically building obstacles to reimbursement, including significant expense criteria and approval processes that hinder con… Read More